RxDoctor Payments Data

Dmitri Vasin, MD

Nephrology · Bremerton, WANPI 1730132689

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $162,566 of the $215,048 with a category attached, or 75.6%. 14 manufacturers reported payments, led by Mallinckrodt Hospital Products Inc. at 32.5% of the total. Reporting peaked in 2019 at $73,803 and has fallen 89.5% since, to $7,784 in 2025. Among nephrology clinicians in WA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$215,048in general payments, 2019–2025

Across 356 payments — averaging $604.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mallinckrodt Hospital Products Inc.$70K
  • Mallinckrodt Enterprises LLC$60K
  • Bayer$45K
  • Vifor Pharma, Inc.$15K
  • Novartis$8K
  • Travere Therapeutics, Inc.$6K
  • plus $11K from 8 others

What the payments were for

  • Consulting fees$15,9507%
  • Speaking & faculty fees$162,56676%
  • Travel & lodging$31,28015%
  • Food & beverage$5,1422%
  • Education$1100%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$215,048 in reported general payments places this provider in the 95th percentile of 237 nephrology providers in Washington.

See all nephrology providers in Washington

Medicare billing

Part B allowed, 2024
$292,545
Medicare patients
647
Services billed
2,230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin15$23,453
FarxigaDapagliflozin Propanediol16$22,583
KerendiaFinerenone11$19,489
Cinacalcet Hcl12$9,853
Nebivolol Hcl86$5,105
Calcium Acetate25$2,978
Carvedilol235$2,954
Sevelamer Carbonate14$2,548
Spironolactone214$1,544
Amlodipine Besylate197$1,391
Calcitriol49$1,286
Eplerenone22$1,258
Olmesartan Medoxomil42$1,014
Nifedipine ErNifedipine31$967
Doxazosin Mesylate41$852

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$118$23,45315 claims
AstraZenecaFarxiga$5,839$22,58316 claims
BayerKerendia$45,216$19,48911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 237 nephrology providers in Washington.

Other nephrology in Bremerton

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →